Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jürg Bernhard

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Health and Quality of Life Outcomes|January 14, 2018
When do patient reported quality of life indicators become prognostic in breast cancer?Chee Khoon Lee, Malcolm Hudson, John Simes, et al.
Arthritis Research & Therapy|March 23, 2016
Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management CohortAdrian Ciurea, Pascale Exer, Ulrich Weber, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 15, 2014
Mandatory communication skills training for oncologists: enforcement does not substantially impact satisfactionCéline Bourquin, Friedrich Stiefel, Jürg Bernhard, et al.
Swiss Medical Weekly|May 30, 2022
Qualitative analysis of facilitators and barriers to centre- and home-based exercise training in breast cancer patients - a Swiss tertiary centre experienceCaroline Schneider, Sina Reimann, Julia Schmid, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 26, 2016
The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial SpondyloarthritisMichael J Nissen, Adrian Ciurea, Jürg Bernhard, et al.
Arthritis Research & Therapy|July 21, 2017
Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritisRaphael Micheroli, Monika Hebeisen, Lukas M Wildi, et al.
Lung Cancer (Amsterdam, Netherlands)|April 25, 2008
Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changesKarin Ribi, Jürg Bernhard, Jan C Schuller, et al.
The Journal of Rheumatology|November 3, 2014
Treatment with tumor necrosis factor inhibitors in axial spondyloarthritis: comparison between private rheumatology practices and academic centers in a large observational cohortAdrian Ciurea, Ulrich Weber, Daniel Stekhoven, et al.
Breast Cancer Research and Treatment|September 21, 2004
Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?Marzio E E Sabbioni, Jürg Bernhard, Hans-Peter Siegrist, et al.
Annals of the Rheumatic Diseases|February 11, 2015
Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritisAdrian Ciurea, Almut Scherer, Ulrich Weber, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Health and Quality of Life Outcomes|January 14, 2018
When do patient reported quality of life indicators become prognostic in breast cancer?Chee Khoon Lee, Malcolm Hudson, John Simes, et al.
Arthritis Research & Therapy|March 23, 2016
Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management CohortAdrian Ciurea, Pascale Exer, Ulrich Weber, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 15, 2014
Mandatory communication skills training for oncologists: enforcement does not substantially impact satisfactionCéline Bourquin, Friedrich Stiefel, Jürg Bernhard, et al.
Swiss Medical Weekly|May 30, 2022
Qualitative analysis of facilitators and barriers to centre- and home-based exercise training in breast cancer patients - a Swiss tertiary centre experienceCaroline Schneider, Sina Reimann, Julia Schmid, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 26, 2016
The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial SpondyloarthritisMichael J Nissen, Adrian Ciurea, Jürg Bernhard, et al.
Arthritis Research & Therapy|July 21, 2017
Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritisRaphael Micheroli, Monika Hebeisen, Lukas M Wildi, et al.
Lung Cancer (Amsterdam, Netherlands)|April 25, 2008
Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changesKarin Ribi, Jürg Bernhard, Jan C Schuller, et al.
The Journal of Rheumatology|November 3, 2014
Treatment with tumor necrosis factor inhibitors in axial spondyloarthritis: comparison between private rheumatology practices and academic centers in a large observational cohortAdrian Ciurea, Ulrich Weber, Daniel Stekhoven, et al.
Breast Cancer Research and Treatment|September 21, 2004
Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?Marzio E E Sabbioni, Jürg Bernhard, Hans-Peter Siegrist, et al.
Annals of the Rheumatic Diseases|February 11, 2015
Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritisAdrian Ciurea, Almut Scherer, Ulrich Weber, et al.
Pageof 6